Ind-Swift gets Japan regulator's nod for 2 drugs

Our Bureau Mumbai | Updated on March 10, 2011 Published on March 10, 2011

Chandigarh-based Ind-Swift Laboratories has received approval from the Japanese Government's pharmaceutical and medical devices agency (PMDA) for the supply of Pioglitazone and Risedronate Sodium from its manufacturing facilities at Derabassi in Punjab.

Mr N.R. Munjal, Managing Director, said that with the approval, the company targets a market share of 15-20 per cent for these products by 2013.

The market for Pioglitazone, an anti-diabetic drug, is estimated at about $2.8 billion while that of Risedronate Sodium, a drug for Osteoporosis, is pegged at $1.6 billion, he added.

The company has already filed four DMFs (drug master files) in Japan including that of Atorvastatin, which commands a $12 billion market. It expects PMDA approval soon. It has filed 302 DMFs so far with various regulatory authorities.

It is for the first time that a large number of drugs patented by Japanese companies are going off-patent. With its healthcare market size of $350 billion and $13 billion worth of pharma product imports, Japan has emerged a promising market for Indian pharma manufacturers.

A rapidly ageing populationand the associated high healthcare expenditure is also increasing the popularity of generics in Japan, said Mr Munjal. India's pharmaceutical exports to Japan are estimated at $10 million.

“We are in advanced stage of negotiations to supply commercial quantities of these products to the Japanese market, and the free trade pact between India and Japan will further strengthen the company's export revenues,” he added.

The company's shares on BSE were down 1.39 per cent at Rs 91 on Thursday.

Published on March 10, 2011

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.